State Street Corp Purchases 605,752 Shares of Eli Lilly and Company $LLY

State Street Corp grew its position in Eli Lilly and Company (NYSE:LLY) by 1.7% during the 2nd quarter, HoldingsChannel reports. The fund owned 36,215,754 shares of the company’s stock after purchasing an additional 605,752 shares during the period. Eli Lilly and Company comprises about 0.9% of State Street Corp’s investment portfolio, making the stock its 18th largest holding. State Street Corp’s holdings in Eli Lilly and Company were worth $43,438,262,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in LLY. Osbon Capital Management LLC purchased a new stake in Eli Lilly and Company in the fourth quarter worth $25,000. Basso Capital Management L.P. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $30,000. Maseco LLP boosted its stake in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after purchasing an additional 28 shares during the period. Aventus Investment Advisors Inc. grew its holdings in shares of Eli Lilly and Company by 270.0% in the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after purchasing an additional 27 shares during the last quarter. Finally, Marshall & Sterling Wealth Advisors Inc. increased its stake in Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after buying an additional 15 shares during the period. Institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly CEO David Ricks said approximately 700,000 seniors have started GLP-1 treatments since Medicare coverage began in July, with Lilly capturing about 70% of those new patients. Foundayo also represents roughly one-third of new oral GLP-1 prescriptions, with its share growing weekly. CNBC Medicare coverage article
• Positive Sentiment: Lilly broke ground on a planned $6.5 billion Houston manufacturing facility that will produce active ingredients for medicines including Foundayo. The project is expected to create more than 600 jobs and strengthen domestic supply capacity. Lilly Houston manufacturing announcement
• Positive Sentiment: Investor Ken Langone said Lilly is becoming one of the largest positions in his portfolio and suggested the stock could eventually reach $2,000. Separately, a major global bank reportedly sees approximately 37% upside after the recent pullback. Ken Langone Lilly outlook
• Neutral Sentiment: Lilly and Dragoneer have indicated interest in Oura’s planned IPO. The investment could provide exposure to consumer health data, but it is not expected to materially affect Lilly’s near-term earnings. Oura IPO article
• Negative Sentiment: Competition remains the principal risk. Viking Therapeutics shares surged after positive obesity-drug data, while Roche also reported encouraging results. The developments raise concerns that Lilly’s current obesity-drug dominance could face stronger competition, pressuring the stock alongside Novo Nordisk. Viking and Roche obesity-drug data

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 over the last ninety days. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Stock Up 0.4%

NYSE:LLY traded up $5.12 during mid-day trading on Tuesday, reaching $1,170.01. The company’s stock had a trading volume of 1,111,489 shares, compared to its average volume of 3,013,810. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 1 year low of $712.05 and a 1 year high of $1,292.65. The stock has a fifty day moving average of $1,176.50 and a 200-day moving average of $1,078.33. The firm has a market capitalization of $1.10 trillion, a PE ratio of 39.28, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter last year, the firm posted $6.31 EPS. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts forecast that Eli Lilly and Company will post 36.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. UBS Group set a $1,376.00 price objective on shares of Eli Lilly and Company in a report on Friday, August 7th. Morgan Stanley restated an “overweight” rating and issued a $1,419.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 6th. Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, HSBC increased their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research note on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,305.25.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.